All News
The RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read ArticleGout Crystal Deposition is Deeper than its Measures
Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT). The total body urate deposition is even greater in those with higher sUA and evidence
Read ArticleProbenecid Benefits Heart Failure
In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation.
Read ArticleThe RheumNow Week in Review - 23 February 2018
Dr Jack Cush reviews highlights from the past week on RheumNow.com. This week’s video is in two parts; for part Ii, go to https://buff.ly/2BM9MjL
Read ArticleT2T Improves Primary Care Gout Management
Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented.
Read ArticleThe RWCS - RheumNow Week in Review - 9 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes news and education from the RWCS meeting in Maui.
Read ArticleThe RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read ArticleThe RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read ArticleNew BSR 2017 Gout Guidelines (Best of 2017)
The British Society for Rheumatology/British Health Professionals in Rheumatology first published a guideline for the management of gout in 2007. They have just updated and published their new guideline, largely because of new therapies, an increasing incidence of gout, low penetrance of urate lowering therapies, and the inability to achieve a target serum uric acid level.
Read ArticleThe RheumNow Week in Review - 22 December 2017
Dr. Jack Cush reviews highlights and news from the past week on RheumNow.com.
Read ArticleAllopurinol Dose Escalation is Safe with Severe CKD
Hypertension, nephrolithiasis and chronic kidney disease (CKD) commonly associates with gout. While there is a clear need to dose adjust NSAIDs and colchicine in those with CKD, there is some debate about the need to dose adjust when using allopurinol with CKD.
Read ArticleRisk of Gout Onset and Flare Linked to Urate Levels
Serum uric acid (SUA) levels are clearly linked to gout. Researchers from Harvard have systemically reviewed the literature to quantify the risk of onset and flare with varying levels of SUA.
Read ArticleThe RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read ArticleFebuxostat Works in Early Gout But Fails to Protect from Xray Damage
Dalbeth and colleagues have published a novel report in Arthritis & Rheumatology, novel in that it is a trial of early gout patients that looks at clinical and radiographic outcomes. They showed that febuxostat improves magnetic resonance imaging (MRI) measures of synovitis and reduced gout flares, but failed to alter X-ray progression with 2 years follow-up.
Read ArticleThe RheumNow Week in Review - 8 December 2017
Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.
Read ArticleThe ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read ArticleGout Associated with Work Absenteeism
Annals of Rheumatic Disease reports that gout is associated with higher work absenteeism and thus, increased costs for society due to productivity loss.
Read ArticleGood News from ACR17 - Gout
The following is a collection of gout-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.
Read ArticlePodcast of ACR 17 - Day 3
Check out this compilation of our ACR17 Day 3 broadcasts, merged into a single one hour podcast !
Read ArticleCardiovascular Events: Allopurinol vs. Febuxostat
In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.
Read Article


